<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480011</url>
  </required_header>
  <id_info>
    <org_study_id>P1101</org_study_id>
    <nct_id>NCT01480011</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with various malignancies who are taken up for high dose chemotherapy followed by&#xD;
      stem cell transplant (blood and marrow transplant) have very high chances of developing&#xD;
      severe oral mucositis (between 95-100%). This mucositis not only causes significant morbidity&#xD;
      but also hampers quality of life so much so that patients at times feel difficult to continue&#xD;
      treatment.&#xD;
&#xD;
      No definite treatment exists for prevention or treatment of oral mucositis in this group of&#xD;
      patients. Though one study has suggested that use of IV palifermin (a keratinocyte growth&#xD;
      factor) will reduce duration and severity. Palifermin is very expensive and not available in&#xD;
      country. Recently the investigators have shown effectiveness of a probiotic Lactobacillus CD&#xD;
      2 in reducing incidence and severity of chemo-radiotherapy induced mucositis in head and neck&#xD;
      squamous cell cancer patients. (Published online in European Journal of Cancer:&#xD;
      http://dx.doi.org/10.1016/j.ejca.2011.06.010). No significant toxicity has been reported with&#xD;
      its use.&#xD;
&#xD;
      Now, the investigators want to study the efficacy of this drug to reduce severity of&#xD;
      mucositis in patients undergoing hematopoietic stem cell transplantation. The drug will be&#xD;
      supplied by CD Pharma India Private Limited.&#xD;
&#xD;
      The investigators further give undertaking that study will be carried as per good clinical&#xD;
      practices (GCP) and declaration of Helsinki.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of grade III and grade IV mucositis</measure>
    <time_frame>Day 24 of stem cell infusion or complete healing of mucositis</time_frame>
    <description>Determine the incidence of grade III and IV mucositis in patients undergoing allogeneic or autologous haematopoietic stem cell transplantation .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>grade I and grade II mucositis</measure>
    <time_frame>Day 24 of stem cell infusion or complete healing of mucositis</time_frame>
    <description>Determine the incidence of Grade I and II mucositis in patients undergoing allogenic or autologous haematopoietic stem cell transplantation.&#xD;
Duration of and time period for healing of chemotherapy induced oral mucositis.&#xD;
Determine incidence and severity of dysphagia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>lactobacillus lozenges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactobacillus CD2 lozenges</intervention_name>
    <description>The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient</description>
    <arm_group_label>lactobacillus lozenges</arm_group_label>
    <other_name>CD#2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 10 and 70 years.&#xD;
&#xD;
          2. Karnofsky Performance Score â‰¥ 70%.&#xD;
&#xD;
          3. Confirmed histological diagnosis of cancer/leukaemia for which haematopoietic stem&#xD;
             cell transplantation is an approved modality of therapy.&#xD;
&#xD;
          4. Patients eligible to receive high-dose chemotherapy as part of conditioning regime.&#xD;
&#xD;
          5. Concomitant co morbid condition if present, controlled by medicines.&#xD;
&#xD;
          6. Serum creatinine 1.8mg/dl.&#xD;
&#xD;
          7. Total bilirubin 2mg/dl.&#xD;
&#xD;
          8. Liver enzymes within three times of normal limit.&#xD;
&#xD;
          9. Expected survival &gt; 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women and lactating mothers.&#xD;
&#xD;
          2. Patients with history of AIDS&#xD;
&#xD;
          3. Patients who have taken any other investigational product in last 4 weeks.&#xD;
&#xD;
          4. Patients having untreated symptomatic dental infection.&#xD;
&#xD;
          5. Patients with WHO Grade 3 or 4 oral Mucositis.&#xD;
&#xD;
          6. Other serious concurrent illness.&#xD;
&#xD;
          7. Inconclusive histological diagnosis.&#xD;
&#xD;
          8. Patients on anticancer antibiotics.&#xD;
&#xD;
          9. Patients with signs and symptoms of systemic infections.&#xD;
&#xD;
         10. Patient's/guardian's refusal to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Sharma, MD,DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr BRA Institute Rotary Cancer Hospital ,All India Institute of Medical Sciences,New Delhi ,India.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>All India institute of Medical sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Sharma A, Rath GK, Chaudhary SP, Thakar A, Mohanti BK, Bahadur S. Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer. 2012 Apr;48(6):875-81. doi: 10.1016/j.ejca.2011.06.010. Epub 2011 Jul 6.</citation>
    <PMID>21741230</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2011</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Dr Atul Sharma</investigator_full_name>
    <investigator_title>Additional Professor Medical Oncology, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lactobacillus CD2 lozenges</keyword>
  <keyword>high-dose chemotherapy induced</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

